DNA vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and operational deterioration. Despite a strong current ratio of 4.92 providing a short-term liquidity buffer, the company is facing a systemic collapse in growth with YoY revenue declining by 23.80%. Massive negative operating margins (-209.74%) and a catastrophic 5-year price decline of 98.1% suggest a failing business model. The combination of shrinking top-line revenue and bearish insider selling confirms a high-risk profile.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
DNA vs MRK: Head-to-Head Comparison
This page compares Ginkgo Bioworks Holdings, Inc. (DNA) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.